Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by wildbird1on May 22, 2023 12:49pm
517 Views
Post# 35459156

The first 25 patients.

The first 25 patients.Here is a little challenge for anybody on this board.
Find just one PressRelease were TLT said that for BTD application, TLT need more than 25 patients data???
You wont find any, from the first day of phase11 trial,TLT has always repeated the same phrase.
" The company will compile a clinical data report for submission to the FDA in support of the grant of a BTD approval after the completion of the 450 days assesment for 25 patients".

Here are interesting numbers on the first 25 patients. I did use the same numbers as the last Swimmer Plot.
-CR at any point in time for the first 25 patients= 21/25 patients=84% CR at any point in time.
-Here is a number that went unnoticed, the response rate(patients that did respond to the treatment at one point in time).
100% of the first 25 patients did respond to TLT treatment at one point in time.
Some for just 90 days, but they still did respond. What would have happened if these patients had received a third treatment?
-For these 25 patients, safety was 100%.

Think about this...
As we speak the FDA has no treatment for the kind of patients TLT is treating( even Adstiladrin doesn't work, as patients who are immunosuppressed, or immune-deficient should not come into contact with Adstiladrin), TLT doesn't have this kind of restrictions.






<< Previous
Bullboard Posts
Next >>